SecBot SecBot
SECBOTREPLAY Home › Report › BNTX

BNTX · BioNTech filed a 6-K announcing its upcoming presentations at the 2026…

BioNTech SE · 6-K filed May 22, 2026 at 08:03 ET

At the news

NEUTRALIMPACT 4/10

6-K filed May 22, 2026 at 08:03 ET

BioNTech filed a 6-K announcing its upcoming presentations at the 2026 ASCO Annual Meeting, including new clinical data for pumitamig (Phase 2 ROSETTA Lung-02 in 1L NSCLC) and gotistobart (Phase 2 PRESERVE-004 in platinum-resistant ovarian cancer), plus four trial-in-progress posters across its ADC and immunotherapy pipeline. The filing is a routine pipeline update with no new financial data, guidance, or regulatory milestones, the clinical data disclosed is interim and descriptive, not definitive.

  • BioNTech will present at ASCO 2026 (May 29–June 2) with two oral presentations and four poster presentations
  • Pumitamig (PD-L1/VEGF-A bispecific) Phase 2 data in 1L NSCLC shows 'encouraging anti-tumor activity', third global dataset with consistent signal
  • Gotistobart (CTLA-4) Phase 2 data in platinum-resistant ovarian cancer shows 'durable anti-tumor activity and clinically meaningful overall survival'
  • Company has 25+ Phase 2/3 trials including 13 ongoing pivotal trials and novel-novel combination trials including ADCs

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access